AIM Notice (17)

RNS Number : 7432G
Immupharma PLC
05 March 2018
 

5 March 2018

 




 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

AIM Rule 17 Notice

 

ImmuPharma PLC (LSE: IMM), specialist drug discovery and development company, announces pursuant to Rule 17 of the AIM Rules for Companies ("AIM Rules"), the following director's disclosure under Schedule Two, Paragraph (g) of the AIM Rules:

 

Tim McCarthy, the Company's Non-executive Chairman, is currently on the board of Harvard Healthcare Limited ("Harvard"). On 5 March 2018 the Directors of Harvard passed a board resolution following which Harvard will be placed into a Creditors' Voluntary Liquidation.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

 

 

-Ends-

For further information please contact:

 

ImmuPharma plc (www.immupharma.org)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman


Lisa Baderoon, Head of Investor Relations

lisa.baderoon@immupharma.com

Twitter: @immupharma

 

+ 44 (0) 7721 413496

 

 

Northland Capital Partners Limited (NOMAD & Broker)

David Hignell, Dugald J. Carlean, Jamie Spotswood, Corporate Finance

Rob Rees, Corporate Broking

+44 (0)20 3861 6625








 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AMOEAKDSEFFPEFF

Companies

Immupharma (IMM)
UK 100